AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsAbbVie continues to diversify its portfolio into neuroscience and aesthetics to offset the loss of patent exclusivity for older drugs.
AbbVie and Johnson & Johnson, two healthcare titans, are navigating a complex market landscape marked by patent expirations and regulatory changes. Each company presents a distinct investment profile, making the choice between the two a matter of balancing aggressive growth potential against diversified stability.
AbbVie, with its focus on high-growth areas such as immunology and neuroscience, aims to counterbalance revenue losses from older blockbuster drugs. The company's global reach, particularly in immunology, oncology, neuroscience, and aesthetics, is underscored by its distribution through major players like McKesson Corp and Cardinal Health, which handle nearly all U.S. sales.
However, this customer concentration introduces a layer of risk. To mitigate this and drive future growth, AbbVie is actively expanding its research capabilities, including a multi-year partnership with artificial intelligence technology.
In contrast, Johnson & Johnson operates as a diversified titan, balancing its innovative medicine segment with a significant medical technology business. This diversification provides a robust foundation for stability. Johnson & Johnson's reputation as a reliable dividend payer, coupled with its substantial scale, makes it an attractive option for investors seeking steady returns alongside growth potential.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
